Patents Assigned to Innovative Cellular Therapeutics, Inc.
-
Patent number: 11970548Abstract: The compositions and methods described herein are directed to treating solid tumors using CAR T therapy and/or antibodies targeting GCC. The compositions include CAR comprising an extracellular domain that binds GCC.Type: GrantFiled: August 23, 2022Date of Patent: April 30, 2024Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Zhiyuan Cao, Yuzhe Peng, Lei Xiao, Zhao Wu, Le Tian
-
Patent number: 11944645Abstract: The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.Type: GrantFiled: September 30, 2021Date of Patent: April 2, 2024Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Zhiyuan Cao, Lei Xiao, Yuzhe Peng, Wei Ding, Wensheng Wang
-
Publication number: 20240075061Abstract: The present disclosure relates to compositions and methods for enhancing infiltration of lymphocytes into tumor tissue, enhancing anti-tumor lymphocyte activities in tumor microenvionment (TME), inhibiting regulatory lymphocyte (e.g., B and T cells) activities in TME, and/or long term benefit of cell therapies. For example, in a method of in vivo cell expansion, the method comprises administering an effective amount of cells comprising an antigen binding molecule to a subject; and administering an effective amount of presenting cells expressing a solid tumor antigen that the binding molecule binds.Type: ApplicationFiled: December 13, 2022Publication date: March 7, 2024Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Wensheng Wang, Dongqi Chen, Chengfei Pu, Zhao Wu, Lei Xiao, Zhiyuan Cao, Le Tian
-
Publication number: 20240058337Abstract: The present disclosure relates to compositions and methods for reducing side effects and/or enhancing cancer treatment that use modified immune cells expressing chimeric antigen receptors (CARs) or modified T cell receptors (TCRs). The modified immune cells, such as T cells or NK cells, can express CARs or TCRs targeting solid tumor antigens, white blood cell antigens like CD19, or bispecific CARs/TCRs targeting both. The methods include administering dasatinib to reduce the side effects associated with CAR T or TCR therapy and/or enhance cancer treatment. The modified cells can co-express additional therapeutic agents like cytokines.Type: ApplicationFiled: August 16, 2023Publication date: February 22, 2024Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, Zhao Wu, Chengfei Pu, Zhiyuan Cao, Dongqi Chen, Xiaobin Lu, Le Tian
-
Publication number: 20240024476Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. For example, the compositions include CAR T cells comprising an extracellular domain that binds FCR1, MSLN, GPC-3, ALPP, CD70, CLDN6, ROR1, CD205, ACPP, ADAM12, or CLDN18.2.Type: ApplicationFiled: January 6, 2022Publication date: January 25, 2024Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Zhiyuan Cao, Xiaogang Shen, Wensheng Wang, Beibei Jia, Dongqi Chen, Xiaoqiang Xu, Xudong Tang, Wei Ding, Xianyang Jiang, Yuzhe Peng, Guiting Han, Le Tian, Zhao Wu, Lei Xiao
-
Patent number: 11858977Abstract: Embodiments relate to a modified cell engineered to comprise a modified TCR-CD3 complex, wherein the CD3?, ?-chain, CD3?, and/or CD3? chains of the modified TCR-CD3 complex are linked to one or more co-stimulatory signaling domains.Type: GrantFiled: October 22, 2020Date of Patent: January 2, 2024Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Dongqi Chen, Xiaogang Shen
-
Patent number: 11833174Abstract: Embodiments relate to a modified cell comprising a polynucleotide encoding a dominant negative form of Death receptor 5 (DR5). In embodiments, the modified cell further comprises a chimeric antigen receptor (CAR) and/or a modified TCR.Type: GrantFiled: September 17, 2020Date of Patent: December 5, 2023Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Zhiyuan Cao, Chengfei Pu, Dongqi Chen, Wei Ding
-
Publication number: 20230322899Abstract: The present disclosure relates to a fusion protein and uses thereof. For example, the fusion protein comprises an extra-cellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is derived from a first molecule, and the intracellular domain is derived from a second molecule. The first molecule is different from the second molecule, and the second molecule comprises OX40, CD40, 4-1 BB, GITR, ICOS, CD28, CD27, HER2, EGFR, EL-10R, IL-12R, IL-18R1, IL-23R, GP130, or IL-15Ra.Type: ApplicationFiled: August 24, 2021Publication date: October 12, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Xiaogang Shen, Zhiyuan Cao, Lei Xiao, Beibei Jia, Le Tian
-
Publication number: 20230293691Abstract: The present disclosure relates to compositions and methods for treating a subject having cancer associated with melanoma-associated antigen 4 (MAGE-A4) peptide. The disclosure includes the embodiments relate to a chimeric antigen receptor (CAR) that binds MAGE-A4 peptide, a polynucleotide encoding a CAR that binds the MAGE-A4 peptide, a modified cell comprising a CAR that binds the MAGE-A4 peptide, and a population of modified cells comprising a CAR that binds the MAGE-A4 peptide.Type: ApplicationFiled: June 9, 2021Publication date: September 21, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Xiaogang Shen, Dongqi Chen, Beibei Jia, Le Tian
-
Publication number: 20230227779Abstract: Embodiments of the present disclosure relate to compositions and methods of enhancing lymphocytes' ability to treat cancer patients. Embodiments relate to a polynucleotide comprising a nucleic acid encoding a chimeric antigen receptor (CAR), a nucleic acid encoding an Oxygen-Dependent Degradation domain (ODD), and a nucleic acid encoding one or multiple sequences of Hypoxia-Response Element (HRE).Type: ApplicationFiled: January 19, 2023Publication date: July 20, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Xiaogang Shen, Xudong Tang, Chengfei Pu, Lei Xiao, Le Tian
-
Publication number: 20230226113Abstract: The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFN?.Type: ApplicationFiled: March 31, 2023Publication date: July 20, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Yang Li, Zhiyuan Cao, Wei Ding, Xianyang Jiang, Chengfei Pu, Le Tian, Christopher Ballas, Zhao Wu, Lei Xiao
-
Publication number: 20230201258Abstract: The present disclosure relates to compositions and methods for enhancing cell response and/or expanding chimeric antigen receptor (CAR) cells and/or maintenance in vivo and/or in vitro. In embodiments, the method comprises obtaining CAR T cells comprising a CAR comprising a binding domain that binds a solid tumor antigen, a transmembrane domain, and an intracellular domain; and contacting the CART cells with white blood cells and a bispecific antibody, such as a Bispecific T cell engager (BiTEĀ®), thereby activating the CAR T cells, wherein the level of activation of the CAR T cells is higher than the level of activation of CAR T ells that are contacted with B cells without the bispecific antibody. The bispecific antibody comprises a first binding domain binding CD3 and a second binding domain binding CD19, CD20, CD22, or BCMA.Type: ApplicationFiled: April 21, 2021Publication date: June 29, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Lei Xiao, Jingrui Liu, Junkai Peng, Le Tian, Xiaogang Shen, Zhiyuan Cao, Zhao Wu
-
Patent number: 11633427Abstract: The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFN?.Type: GrantFiled: February 4, 2022Date of Patent: April 25, 2023Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Yang Li, Zhiyuan Cao, Wei Ding, Xianyang Jiang, Chengfei Pu, Le Tian, Christopher Ballas, Zhao Wu, Lei Xiao
-
Publication number: 20230074145Abstract: The compositions and methods described herein are directed to treating solid tumors using CAR T therapy and/or antibodies targeting GCC. The compositions include CAR comprising an extracellular domain that binds GCC.Type: ApplicationFiled: August 23, 2022Publication date: March 9, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Zhiyuan Cao, Yuzhe Peng, Lei Xiao, Zhao Wu, Le Tian
-
Publication number: 20230032871Abstract: The present disclosure relates to systems and methods for immune therapy. For example, a method can be used to enhance proliferation of chimeric antigen receptor (CAR) T cells in a patient, The method comprises administering to the patient an effective amount of a pharmaceutical composition comprising lymphocyte activation agents and one or more recombinant viral particles comprising a polynucleotide encoding a CAR, wherein the proliferation of CAR T cells in the patient is greater as compared to a patient administered with the one or more recombinant viral particles but without the lymphocyte activation agents.Type: ApplicationFiled: July 14, 2022Publication date: February 2, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Zhiyuan Cao, Wei Ding, Guiting Han, Lei Xiao, Le Tian
-
Publication number: 20220348682Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.Type: ApplicationFiled: August 29, 2019Publication date: November 3, 2022Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, He Sun, Zhiyuan Cao, Wensheng Wang, Chengfei Pu, Li Mao
-
Publication number: 20220265708Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.Type: ApplicationFiled: January 10, 2019Publication date: August 25, 2022Applicants: Innovative Cellular Therapeutics, Inc., Innovative Cellular Therapeutics Co., Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu, Li Mao, Mao Bi
-
Publication number: 20220249557Abstract: The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFN?.Type: ApplicationFiled: February 4, 2022Publication date: August 11, 2022Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Yang Li, Zhiyuan Cao, Wei Ding, Xianyang Jiang, Chengfei Pu, Le Tian, Christopher Ballas, Zhao Wu, Lei Xiao
-
Publication number: 20220105134Abstract: The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.Type: ApplicationFiled: September 30, 2021Publication date: April 7, 2022Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Zhiyuan Cao, Lei Xiao, Yuzhe Peng, Wei Ding, Wensheng Wang
-
Publication number: 20210379149Abstract: Embodiments relate to a method for increasing or maintaining a population of memory T-cells. The method includes introducing T-cells with a nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR includes an extracellular domain, a transmembrane domain, and an intracellular domain, and the extracellular domain binds an antigen; introducing into the T-cells a nucleic acid encoding a modified PD-1, wherein the modified PD-1 lacks a functional PD-1 intracellular domain; and administering an effective amount of a composition comprising the T-cells to a subject having cancer.Type: ApplicationFiled: October 25, 2019Publication date: December 9, 2021Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Zhiyuan Cao, He Sun, Zhao Wu, Lei Xiao